drugset
drugset / Trial / NCT00640315

Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.

NCT00640315 ↗

Phase 1 Completed 23 enrolled Bayer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).

Timeline

Start
2008-08
Primary completion
2009-09
Completion
2009-09

Publications

  • Results H.-A. Ghofrani, G. Staehler, E. Gruenig, M. Halank, V. Mitrovic, S. Unger, W. Mueck, R. Frey, J. Behr. The Effect Of The Soluble Guanylate Cyclase Stimulator Riociguat On Hemodynamics In Patients With Pulmonary Hypertension Due To Chronic Obstructive Pulmonary Disease. D96 CLINICAL TRIALS AND OUTCOMES IN PULMONARY HYPERTENSION.

Drugs

EvaluationDrugModalityDoseRoute
Subject Riociguat Other / unclassified 1 mg Oral
Subject Riociguat Other / unclassified 2.5 mg Oral

Indications

chronic obstructive pulmonary disease pulmonary hypertension